S-Adenosyl-L-Homocysteine (SAH) Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 370

Clinical Trials

Numerous clinical trials evaluate S-adenosyl-L-homocysteine (SAH) across various indications, primarily subarachnoid hemorrhage, traumatic brain injury, stroke, circadian rhythm disorders, endometriosis, and severe alcoholic hepatitis. Spanning Phase 1 and 2 exploratory evaluations to Phase 4 interventional and observational studies, these protocols are sponsored by academic medical centers and commercial entities like Cumberland Pharmaceuticals. Current recruitment statuses across these studies range from not yet recruiting and active to completed and terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06803043	ENROLLING_BY_INVITATION	Domestic Violence; Post Traumatic Stress Disorder	Boston University	2025-02-13
NCT07761520	NOT_YET_RECRUITING	Aneurysmal Subarachnoid Hemorrhage	Centre Hospitalier Universitaire de Nice	2026-09
NCT06735261	NOT_YET_RECRUITING	Subarachnoid Hemorrhage in Adult Patients	University Hospital, Grenoble	2025-04-01
NCT06526247	RECRUITING	Intimate Partner Violence	Boston University	2024-11-18
NCT03845205	RECRUITING	Alcohol Use Disorder; Alcoholic Hepatitis	Johns Hopkins University	2020-11-20
NCT04578249	RECRUITING	Circadian Rhythm Disorders	West Virginia University	2021-09-20
NCT03754725	ACTIVE_NOT_RECRUITING	SAH; Dementia	Duke University	2020-10-01	PHASE1; PHASE2
NCT06890039	NOT_YET_RECRUITING	Acute-On-Chronic Liver Failure; Alcoholic Hepatitis; Liver Cirrhosis, Alcoholic	Yaqrit Ltd	2025-09-01	PHASE2
NCT06060756	Not yet recruiting	Endometriosis\|Obstructive Sleep Apnea-hypopnea	Elsan	2024-05	--
NCT03249207	UNKNOWN	Subarachnoid Hemorrhage	University of Manchester	2018-10-11	PHASE3
NCT06119061	Recruiting	Subarachnoid Hemorrhage Aneurysmal	Aaron Cook\|Cumberland Pharmaceuticals\|University of Kentucky	2024-02-29	Phase 4
NCT05994794	COMPLETED	Elevated S-adenosylhomocysteine	Standard Process Inc.	2022-12-09
NCT03691727	COMPLETED	Subarachnoid Hemorrhage, Aneurysmal	David Hasan	2019-01-24	PHASE1; PHASE2
NCT03319173	COMPLETED	Mild Cognitive Impairment; Metabolic Syndrome	Bristlecone Health, Inc.	2017-10-15
NCT02323685	COMPLETED	Cerebral Ischemia	Prolong Pharmaceuticals	2014-12	PHASE2
NCT01799525	COMPLETED	Aneurysmal Subarachnoid Hemorrhage	Wuerzburg University Hospital	2013-01	PHASE1
NCT00830843	COMPLETED	Stroke; Subarachnoid Hemorrhage	Azienda Ospedaliera San Gerardo di Monza	2009-01	PHASE4
NCT00626574	TERMINATED	Subarachnoid Hemorrhage	University of South Florida	2007-07	PHASE4
NCT00199706	COMPLETED	Subarachnoid Hemorrhage	Oslo University Hospital	2002-04	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-23)

Check the S-Adenosyl-L-Homocysteine (SAH) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

S-Adenosyl-L-homocysteine (SAH) binds to and potently inhibits the METTL3-METTL14 heterodimer complex with an IC50 of 0.9 μM, thereby blocking methyl group transfer to adenosine residues and suppressing N6-methyladenosine (m6A) RNA modification. This enzymatic inhibition alters downstream gene expression and cell survival pathways, providing therapeutic relevance for addressing cellular stress and injury responses in conditions under clinical evaluation such as subarachnoid hemorrhage and traumatic brain injury.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).